𝛼SK or Search

ENTITY

MetaVia (MTVA US)

24

Analysis

Health Care • United States

MetaVia Inc. operates as a clinical-stage biotechnology company. The Company focuses on developing dual oxyntomodulin (OXM) analog agonist for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). MetaVia serves customers worldwide.

more

Refresh

Exchange Announcement • 13 Oct 2026 20:35

Current Report (Form 8-K | Period ending 2026-10-13)

Exchange Announcement • 09 Sep 2026 21:00

Current Report (Form 8-K | Period ending 2026-09-09)

Exchange Announcement • 07 Aug 2026 04:05

Current Report (Form 8-K | Period ending 2026-08-06)

Exchange Announcement • 06 Aug 2026 08:00

Quarterly Report (Form 10-Q | Period ending 2026-06-30)

Exchange Announcement • 09 Jul 2026 20:35

Current Report (Form 8-K | Period ending 2026-07-09)

Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.70.4

x